The forecast for the insulin dosage market size per capita in Germany shows a consistent decline from $28.96 in 2024 to $25.29 in 2028. For context, the market stood at $29.90 per capita in 2023. The year-on-year variation from 2024 onwards reflects a decline of around 3.3% to 3.5% annually. Over the last two years (2023-2024), the market decreased by approximately 3.1%. The compound annual growth rate (CAGR) over the five-year period from 2024 to 2028 averages an annual decrease of roughly 3.5%.
Key future trends to watch for:
- Ongoing advancements in insulin delivery systems and personalized medicine.- Increased competition from biosimilar products.- Regulatory changes impacting pricing and reimbursement.- Potential shifts in healthcare funding and policy strategies.- Rising awareness and prevention strategies for diabetes management.
